Market Place
Sourcing Support
BMS Named to Dow Jones Sustainability Index North America
10 Jan 2025 //
ACCESSWIRE
BMS to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
03 Jan 2025 //
BUSINESSWIRE
FDA approves BMS` subcutaneous Opdivo with some limitations
02 Jan 2025 //
FIERCE PHARMA
BMS secures subcutaneous Opdivo approval
28 Dec 2024 //
FDA
BMS`s Biologic Opdivo Qvantig Receives Approval in US
27 Dec 2024 //
FDA
Sotyktu has excelled in 2 psoriatic arthritis trials, BMS says
26 Dec 2024 //
FIERCE PHARMA
Bristol Myers Squibb Receives EC Approval for Opdivo + Yervoy in CRC
23 Dec 2024 //
BUSINESSWIRE
BioArctic Signs Global License with Bristol Myers Squibb
19 Dec 2024 //
PR NEWSWIRE
Bristol Myers Squibb to Report Q4 2024 Results on Feb 6, 2025
19 Dec 2024 //
BUSINESSWIRE
BMS pays Leqembi originator $100M for Alzheimer`s prospects
19 Dec 2024 //
FIERCE BIOTECH
BMS’ Cobenfy tipped to be top dog in growing schizophrenia space
19 Dec 2024 //
FIERCE PHARMA
BMS pays Leqembi originator $100M for Alzheimer’s prospects
19 Dec 2024 //
FIERCE BIOTECH
Fangzhou Partners with Bristol Myers Squibb on Internet Healthcare
18 Dec 2024 //
PR NEWSWIRE
Insitro Receives $25M in Milestone Payments from Bristol Myers Squibb
18 Dec 2024 //
BUSINESSWIRE
Bristol Myers culls cell therapy deals with 2 biotechs
17 Dec 2024 //
FIERCE BIOTECH
Bristol Myers Squibb Announces Dividend Increase
11 Dec 2024 //
BUSINESSWIRE
Acadia nabs Lexicon alum as new commercial lead
11 Dec 2024 //
FIERCE PHARMA
Bristol Myers Squibb Highlights Cell Therapy Portfolio at ASH 2024
09 Dec 2024 //
BUSINESSWIRE
BMS taps AI Proteins in discovery collaboration worth up to $400M
04 Dec 2024 //
FIERCE BIOTECH
Bristol Myers Sues Federal Government Over 340B Drug Pricing
27 Nov 2024 //
ENDPTS
BMS to Participate in Citi’s 2024 Global Healthcare Conference
26 Nov 2024 //
BUSINESSWIRE
BMS cuts 195 jobs, bringing head count reduction to 1,329 in NJ
25 Nov 2024 //
FIERCE PHARMA
NJ biopharmas make pledge to give time off for clinical trials
20 Nov 2024 //
FIERCE BIOTECH
Bristol Myers Squibb Highlights Hematology Portfolio at ASH 2024
19 Nov 2024 //
BUSINESSWIRE
EU regulators endorse meds from BMS, J&J, Eisai and more
15 Nov 2024 //
FIERCE PHARMA
BMS Receives CHMP Opinion for Repotrectinib in ROS1+ NSCLC
15 Nov 2024 //
BUSINESSWIRE
BMS Receives CHMP Opinion for Opdivo® & Yervoy® in MSI-H mCRC
15 Nov 2024 //
BUSINESSWIRE
BMS` CAR-T cracks down on lupus, achieving sustained responses
14 Nov 2024 //
FIERCE BIOTECH
BMS Faces $6.7B Lawsuit Over Delayed Cancer Drug
14 Nov 2024 //
REUTERS
BMS showcases cardiovascular portfolio at AHA Scientific Sessions
14 Nov 2024 //
INDPHARMAPOST
BMS Stock Soars After AbbVie’s Schizophrenia Trial Disappoints
11 Nov 2024 //
MARKETWATCH
Bristol Myers Squibb Showcases Cardiovascular Data at AHA 2024
11 Nov 2024 //
BUSINESSWIRE
Bristol Myers to Participate in Upcoming Investor Conferences
05 Nov 2024 //
BUSINESSWIRE
As new drugs deliver, BMS explores further efficiency moves
31 Oct 2024 //
FIERCE PHARMA
Bristol Myers Squibb Reports Q3 2024 Financial Results
31 Oct 2024 //
BUSINESSWIRE
Bristol Myers Presents Long-term EMERGENT Data in Schizophrenia
31 Oct 2024 //
BUSINESSWIRE
BMS partner Zai Lab eyes China filing for KarXT after trial win
29 Oct 2024 //
FIERCE PHARMA
Bristol Myers Squibb to Present Data at Psych Congress 2024
28 Oct 2024 //
BUSINESSWIRE
Redwire Announces Spaceflight Mission with Bristol Myers
23 Oct 2024 //
BUSINESSWIRE
S1P Receptor Modulators Face Uncertain Future In Crohn’s Disease
14 Oct 2024 //
EXPRESSPHARMA
MEDiC Life Announces Collaboration with Hanmi Pharmaceutical
14 Oct 2024 //
BUSINESSWIRE
MEDiC Life Sciences Secures $5M From LG And Hanmi For Cancer
14 Oct 2024 //
BUSINESSWIRE
BMS` schizophrenia gem Cobenfy was salvaged from the scrapheap
07 Oct 2024 //
FIERCE PHARMA
BMS` Opdivo joins lung cancer treatment ring with key FDA approval
04 Oct 2024 //
FIERCE PHARMA
Bristol Myers`s Biologic Opdivo (Nivolumab) Receives Suppl Approval in US
03 Oct 2024 //
FDA
BMS skates again on $6.4B Celgene shareholder lawsuit
02 Oct 2024 //
FIERCE PHARMA
BMS pays Prime $110M to form T-cell therapy pact
01 Oct 2024 //
PRESS RELEASE
Bristol Myers Squibb Presents New Data On Sotyktu Efficacy
27 Sep 2024 //
BUSINESSWIRE
US FDA approves Bristol Myers` schizophrenia drug
27 Sep 2024 //
REUTERS
Experts back FDA`s plan to restrict PD-1 drugs in GI cancers
26 Sep 2024 //
FIERCE PHARMA
BMS, 2seventy scrap Abecma trial in first-line multiple myeloma
26 Sep 2024 //
FIERCE PHARMA
FDA challenges broad use of PD-1 drugs in stomach cancer
24 Sep 2024 //
FIERCE PHARMA
BMS Cuts 79 More Jobs In NJ As $1.5B Cost-Cut Program Rolls
20 Sep 2024 //
FIERCE PHARMA
Long-Term Zeposia Data Show Efficacy, Safety in Multiple Sclerosis
18 Sep 2024 //
BUSINESSWIRE
Immatics Presents TCER IMA401 Phase 1 Data At ESMO 2024
16 Sep 2024 //
GLOBENEWSWIRE
Schizophrenia Space Awaits First-In-Class FDA Approval For KarXT
16 Sep 2024 //
BIOSPACE
Bristol Myers axes Immatics` bispecific after $150M bet
16 Sep 2024 //
FIERCE BIOTECH
BMS Shows 10-Year Survival Data For Opdivo-Yervoy In Advanced Melanoma
15 Sep 2024 //
BUSINESSWIRE
GSK`s Zejula Misses Survival Goal In First-Line Ovarian Cancer
14 Sep 2024 //
FIERCE PHARMA
Bristol Myers Squibb To Report Q3 2024 Results On October 31
12 Sep 2024 //
BUSINESSWIRE
